An Israeli biotech has developed an investigational, proprietary protein oral delivery (POD™) technology in the development of oral vaccines that are now only available via an imposing injection. Called Oravax, the parent company Oramed reports that the exclusive owner of a virus-like particle (VLP) vaccine technology that targets three SARS-CoV-2 virus surface proteins, including proteins less susceptible to mutation, making the vaccine potentially more effective against current and future variants of the COVID-19 virus. The VLP vaccine has been in the preclinical research process against COVID-19 variants, including the Delta variant. Oravax’s VLP vaccine technology is purportedly highly scalable with a low cost of goods and easily transferable.
The Clinical Trial
Now Oravax, again part of Oramed, gears up to commence clinical trials for its oral COVID-19 vaccine, first in Israel and then in additional clinical trial sites around the world. The study protocol has been approved by the Institutional Review Board (IRB) at Ichilov Hospital in Tel Aviv, Israel, and is now pending approval from the Israeli Ministry of Health. Additionally, the company has commenced GMP manufac...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).